Alto Neuroscience, Inc.

Alto Neuroscience is a clinical-stage biopharmaceutical company founded in 2019 by Stanford psychiatry professor Amit Etkin, focused on precision medicines for mental health . The company went public on the NYSE in February 2024 under ticker ANRO, raising over $129 million at a $16 per share offering price . Its approach centers on identifying brain biomarkers—through cognitive testing, EEG, and wearable data—to match patients with drugs more likely to work for their specific neural profiles, aiming to improve on the high failure rates of traditional psychiatric drug development .

At the time of its listing, Alto had five clinical-stage programs targeting major depressive disorder and schizophrenia populations defined by specific biomarkers, with its lead candidates ALTO-100 and ALTO-300 already through Phase IIa trials . Gaorong Ventures participated in Alto's Series C in 2023 .